《大行》花旗予药明康德(02359.HK)“买入”评级 目标价95元

阿斯达克财经
29 Jul

花旗发表研究报告指,药明康德(02359.HK) 上半年收入按年增长21%至208亿元人民币,期内净利润增长102%至86亿元人民币,若撇除一次性收益增幅为26%,符合此前盈喜公告。管理层已将全年收入指引由原预期的415亿至430亿元人民币,上调至介乎425亿至435亿元人民币,预料持续经营业务增长13%至17%,原预期增长10%至15%,并有信心进一步提升经调整净利率。

花旗基于估值给予药明康德目标价95元,评级为“买入”,将在业绩电话会议后再作更新。(gc/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-07-29 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10